Multiparametric Monitoring of Disease Progression in Contemporary Patients with Wild-Type Transthyretin Amyloid Cardiomyopathy Initiating Tafamidis Treatment
Authors:
- Svenja NeySNSvenja Ney
- Roman Johannes GertzRGRoman Johannes Gertz
- Lenhard PennigLPLenhard Pennig
- Richard J. NiesRNRichard J. Nies
- Udo HoltickUHUdo Holtick
- Linus A. VölkerLVLinus A. Völker
- Gilbert WunderlichGWGilbert Wunderlich
- Katharina SeutheKSKatharina Seuthe
- Christopher HohmannCHChristopher Hohmann
- Clemens MetzeCMClemens Metze
- Claas Philip NähleCNClaas Philip Nähle
- Jennifer von SteinJSJennifer von Stein
Open Access
- 4 January 2024
- journal article
- research article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (1) , 284
Abstract
Background: Recently, a disease modifying therapy has become available for transthyretin amyloid cardiomyopathy (ATTR-CM). A validated monitoring concept of treatment is lacking, but a current expert consensus recommends three clinical domains (clinical, biomarker and ECG/imaging) assessed by several measurable features to define disease progression. Methods: We retrospectively analyzed data of wild-type ATTR-CM patients initiating tafamidis therapy assessed within our local routine protocol at baseline and 6-months follow-up with respect to the frequency of values beyond the proposed thresholds defining disease progression. Additionally, associations of cardiac magnetic resonance (CMR) tomography with clinical domains were examined within a subgroup. Results: Sixty-two ATTR-CM patients were included (88.7% male, mean age 79 years). In total, 16.1% of patients had progress in the clinical and functional domain, 33.9% in the biomarker domain and 43.5% in the imaging/electrocardiography (ECG) domain, with the latter driven by deterioration of the diastolic dysfunction grade and global longitudinal strain. In total, 35.5% of patients showed progress in none, 35.5% in one, 29.0% in two and no patient in three domains, the latter indicating overall disease progression. A subgroup analysis of twenty-two patients with available baseline and follow-up CMR data revealed an increase in CMR-based extracellular volume by more than 5% in 18.2% of patients, with no significant correlation with progress in one of the clinical domains. Conclusions: We provide first frequency estimates of the markers of disease progression according to a recent expert consensus statement, which might help refine the multiparametric monitoring concept in patients with ATTR-CM.Keywords
Funding Information
- Pfizer. Linus A. Völker received research funding and consulting fees from Alexion, AstraZeneca, Bayer (413543196)
- Sanofi-Genzyme (413543196)
- Cologne Clinician Scientist Program (CCSP)/Faculty of Medicine/University of Cologne (413543196)
- Deutsche Forschungsgemeinschaft (413543196)
This publication has 28 references indexed in Scilit:
- Nonbiopsy Diagnosis of Cardiac Transthyretin AmyloidosisCirculation, 2016
- Recommendations for the Evaluation of Left Ventricular Diastolic Function by Echocardiography: An Update from the American Society of Echocardiography and the European Association of Cardiovascular ImagingJournal of the American Society of Echocardiography, 2016
- Gradient Spin Echo (GraSE) imaging for fast myocardial T2 mappingJournal of Cardiovascular Magnetic Resonance, 2015
- Recommendations for Cardiac Chamber Quantification by Echocardiography in Adults: An Update from the American Society of Echocardiography and the European Association of Cardiovascular ImagingJournal of the American Society of Echocardiography, 2015
- Quantification of Myocardial Extracellular Volume Fraction in Systemic AL AmyloidosisCirculation: Cardiovascular Imaging, 2013
- T1 Mapping Shows Increased Extracellular Matrix Size in the Myocardium Due to Amyloid DepositionsCirculation: Cardiovascular Imaging, 2012
- Immunohistochemistry in the classification of systemic forms of amyloidosis: a systematic investigation of 117 patientsBlood, 2012
- Predictors of elevated NT-pro-BNP in cardiovascular patients without acute heart failureInternational Journal of Cardiology, 2009
- Modified Look‐Locker inversion recovery (MOLLI) for high‐resolution T1 mapping of the heartMagnetic Resonance in Medicine, 2004
- Simplified Calculation of Body-Surface AreaNew England Journal of Medicine, 1987